Since 2013, the HITAP International Unit (HIU) has been providing technical support to various developing countries such as Indonesia, Vietnam, Bhutan, and India by sharing the Thai experience in generating and using health technology assessment (HTA) to inform policy decisions. HITAP works in colla

As we approach the end of an unprecedented year, the approval of select COVID-19 vaccines by stringent regulatory authorities and programmatic roll-out has been cause for optimism. However, it is imperative to assure equitable access to those in need in all regions of the world as a core component o

This cost-utility analysis was conducted as the result of a request from the Subcommittee for Development of the NLEM to provide information on the long-term effectiveness and cost-effectiveness of the screening of osteoporosis and its medical management. This information was then used to inform the Subcommittee regarding the selection of osteoporo

Introduction: The development of new technology to treat patients with metastatic renal cell carcinoma has resulted in promising outcomes in terms of extending life and improving quality of life. In Thailand, where health resources are limited, an economic evaluation of such technology would provide useful information for pricing and reimbursement

The Thailand Ministry of Public Health - U.S. Centers for Disease Control and Prevention Collaboration (TUC) in collaboration with partners in Thailand, Cambodia and Vietnam, conducted a clinical study resulting in a new algorithm for pulmonary tuberculosis (PTB) detection. The newly proposed algorithm consists of three initial symptom screening cr

Bhutan is a rapidly growing economy that is transitioning from international donor support. As such, the country is looking for ways to ensure that they continue to provide the adequate services and support for their population in a rational and sustainable manner. Bhutan has begun using health tech

Abstract BACKGROUND: Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis

This study aims to determine the cost-effectiveness and cost-utility of medical rehabilitation services for inpatients suffering from a stroke. It will compare the outcome of medical rehabilitation services in terms of functional status and quality of life before and after service providing. Moreover, it will compare cost-effectiveness and cost-uti

Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Waranya Rattanavipapong1, Tanunya Koopitakkajorn1, Naiyana Praditsitthikorn1,2,*, Surakameth Mahasirimongkol3 andYot Teerawattananon1 Summary Purpose There is strong evidence o

In Thailand, the prevalence of chronic kidney disease (CKD) is 17.5% of the population (Ingsathit et al., 2010). According to Thailand’s National Health Security Office (2021), in each year, this public health agency spends approximately 10,000 million Baht in renal dialysis and 1,000 million Baht for the CKD treatment and other related expenses.